Abiraterone Acetate Followed By Enzalutamide In Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Treated In The Us Oncology Community Setting.

e16061 Background: Both abiraterone acetate (AA) and enzalutamide (enza) are highly effective in men with chemo naive mCRPC. AA was FDA approved in this setting in 2012, and enza in 2014 and thus many physicians use AA followed by enza. Although there are published data on sequencing of AA followed by enza, most of these reports are in the post-chemo setting. There are limited data on the effectiveness, of AA followed by enza when both agents are given in the chemo-naive setting. This study was conducted to assess this in 22 sites in a community setting. Methods: This retrospective, observational cohort study used the iKnowMed (iKM) electronic medical record and chart review to evaluate mCRPC pts who received AA followed by enza (both in the chemo-naive setting) from 1/1/2011 to 12/31/2013 and followed through 4/30/14. 168 pts were identified, 136 pts were evaluable, of whom 24 pts initiated enza before termination of AA. Results: Pt characteristics for 136 pts: median age: 77 yrs (range, 50–93), Caucasia...